Navigation Links
PTC Therapeutics Closes $30 Million Financing
Date:7/23/2012

SOUTH PLAINFIELD, N.J., July 23, 2012 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $30 million financing. The round included a number of long-term investors such as Credit Suisse First Boston Equity Partners, HBM BioVentures, Vulcan Ventures, Celgene, Delphi Ventures, The Column Group, Novo A/S, and other existing investors. 

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

"This funding will support our continued late-stage clinical development of ataluren in nonsense mutation Duchenne and Becker muscular dystrophy and nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "This is our first equity financing round in over two years, and serves as an important validation of the ataluren program and our commitment for its further development." 

PTC recently announced results from a Phase 3 study of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis. An extension study for patients previously enrolled in the trial is ongoing. An open-label trial for Duchenne and Becker muscular dystrophy patients who received ataluren in a prior, PTC-sponsored clinical study is also ongoing while PTC continues the dialogue with regulatory authorities regarding next steps in ataluren's development. In both Duchenne and Becker muscular dystrophy and cystic fibrosis, ataluren has demonstrated clinically meaningful trends in the primary endpoints and in supporting secondary endpoints. It was generally well tolerated; serious adverse events were infrequent and not considered to be related to the drug. PTC owns the worldwide rights for ataluren across all indications.

About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare genetic disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and that have served as the basis for collaborations with leading biopharmaceutical companies such as AstraZeneca, Celgene, Genzyme, Merck, Pfizer and Roche. For more information, visit the company's website at www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
2. Amsterdam Molecular Therapeutics (AMT) Holding N.V. (in liquidation) Announces Publication of its Accounts for 2011 and Notice of Annual General Meeting
3. Echo Therapeutics Expands License Agreement with Ferndale Pharma
4. PTC Therapeutics Announces Achievement of Major Milestone in Wellcome Trust BMI1 Collaboration
5. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
6. NIPTE Will Participate in NIHs Therapeutics for Rare and Neglected Diseases (TRND) Program
7. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
8. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
9. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
10. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
11. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... LONDON , May 30, 2016 ... to eliminate viral hepatitis by 2030. At the 69 th ... first ever Global Viral Hepatitis Strategy, signalling the greatest global ... sets a goal of eliminating hepatitis B and C by ... which, if reached, will reduce annual deaths by 65% and ...
(Date:5/30/2016)... Eye expert s advise ... before leaving hospital to ... Eye Hospital Dubai, the first overseas branch of the world-renowned Moorfields ... babies as a special concern in the region when it comes ... prematurity (ROP). ROP is a potentially blinding condition that affects premature ...
(Date:5/27/2016)... May 27, 2016 According to ... hypertension is driving ambulatory blood pressure monitoring system market ... and their ability to respond to different pressure rates, ... can lead to various cardiovascular disorders such as heart ... These diseases are growing in prevalence each year. WHO ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
(Date:5/27/2016)... , ... May 27, 2016 , ... Two director-level employees ... YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The award recognizes businesswomen ... For this year, Geri Boone, Director of the MLTSS (Managed Long-Term Services and Supports) ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... An ... returns for a third time to shed lights on the variety of topics detailing ... inspirational stories, “Nurse Appreciation” tackles why this career has gone from being in a ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a path to ... society can control and change. , As nearly 795,000 Americans suffering from a new ... United States. Plus, with an estimated 129,000 of these people dying from stroke, it’s ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
Breaking Medicine News(10 mins):